ClinicalTrials.gg
RecruitingNCT07169994Updated Sep 12, 2025

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of YL202 for injection; Toripalimab injection and YL202 for injection; Furmonertinib Mesilate Tablets in Advanced Solid Tumors, Breast Cancer and Non Small Cell Lung Cancer, sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Recruiting at 20 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
414
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing toripalimab in Breast Neoplasms — 9 open to participants now, 10 under way, 1 of them phase 3. toripalimab · Breast Neoplasms.

Planned enrollment
Largest of 14
414 · median 72
Started
2025
with 3 others
Phase 1/2
Only one
of the 14
Registered
11th of 14
by date
Lead sponsor
1 of 14
MediLink Therapeutics (Suzhou) Co., Ltd.

Among the 14 studies testing toripalimab in Breast Neoplasms, this one has the largest planned enrollment, is one of 4 that started in 2025, is the only one in phase 1/2, and was the 11th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 14 studies testing toripalimab in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About toripalimab

toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing toripalimab in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors

03

Conditions studied

  • Advanced Solid Tumors
  • Breast Cancer
  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Informed of the study before the start of the study and voluntarily sign their name and date in the form (ICF)
  2. Able and willing to comply with protocol visits and procedures
  3. Aged between 18 to 75 years
  4. performance status (ECOG PS) of 0 or 1
  5. Previously treated by standard treatment or have not been treated for setting;
  6. Adequate organ and bone marrow function.
  7. Have at least 1 extracranial measurable tumor lesion.
  8. Adequate archival formalin-fixed paraffin embedded (FFPE) tissue from prior .

Exclusion criteria

Exclusion Criteria:

  1. With prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates [ADCs]), chimeric antigen receptor T-cell immunotherapy (CAR-T), and other drugs).
  2. Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors.
  3. Are participating in another clinical study, unless it is an observational (non-interventional) clinical study or in the follow-up period of an interventional study.
  4. The from the previous anti-tumor therapy is insufficient before the first dose of the product.
  5. Patients who have received major surgery (excluding diagnostic surgery) within 4 weeks before the first dose of the investigational product or those who are expected to receive major surgery during the study.
  6. Prior treatment with bone marrow transplantation or solid organ transplantation.
  7. Prior treatment with systemic (prednisone > 10 mg/day or equivalent) or other treatment within 2 weeks before the first dose of the investigational product.
  8. Patients who have received any within 4 weeks before the first dose of the investigational product or those who plan to receive live vaccine during the study period.
  9. With meningeal or cancerous meningitis.
  10. With or spinal cord compression.
  11. Patients with uncontrolled or cardiovascular diseases.
  12. Clinically significant complicated pulmonary disorders.
  13. Patients diagnosed with Gilbert syndrome.
  14. Those with uncontrolled effusion in the third space requiring repeated drainage.
  15. With a medical history of gastrointestinal perforation and/or fistula within 6 months before the first dose, or with active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal diseases that may lead to hemorrhage or perforation according to the investigator.
  16. With serious infection before the first dose.
  17. With known (HIV) infection.
  18. With active virus (HBV) or virus (HCV) infection.
  19. With a medical history of any other primary within 5 years before the first dose of the investigational product.
  20. Unrelieved toxicity of previous anti-tumor therapy.
  21. With a history of severe to inactive ingredients in the raw materials and drug product or other monoclonal antibodies.
  22. Lactating women, or women who are confirmed pregnant via a pregnancy test within 3 days before the first dose.
  23. With any diseases, medical conditions, organ system dysfunction, or social conditions that may interfere with the ability of subjects to sign the ICF, adversely affect the ability of subjects to cooperate and participate in the study, or affect the interpretation of study results, including but not limited to mental illness or substance/alcohol abuse, in the opinion of the investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
414 participants (estimated)

Study arms

  • Experimental
    YL202 in combination with Toripalimab

    Part 1 (dose escalation stage and backfill stage) \& Part 3 (dose expansion stage): YL202 for injection in combination with Toripalimab injection

    Drug: YL202 for injection; Toripalimab injection

  • Experimental
    YL202 in combination with Furmonertinib Mesilate

    Part 2 (dose escalation stage and backfill stage) \& Part 4 (dose expansion stage): YL202 for injection in combination with Furmonertinib Mesilate Tablets

    Drug: YL202 for injection; Furmonertinib Mesilate Tablets

Interventions

  • DrugYL202 for injection; Toripalimab injection

    Drug pages: Beruzatatug pelitecan · Toripalimab

    Part 1: YL202 and Toripalimab will be administered intravenously. Part 3: participants will receive escalating doses of YL202 and fixed dose of Toripalimab until YL202 doses for optimization are determined. Dose expansion stage: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Toripalimab

  • DrugYL202 for injection; Furmonertinib Mesilate Tablets

    Drug pages: Beruzatatug pelitecan · Aflutinib

    Part 2: YL202 will be administered intravenously,Furmonertinib Mesilate Tablets will be administered orally. Dose escalation stage: participants will receive escalating doses of YL202 and fixed dose of Furmonertinib Mesilate until YL202 doses for optimization are determined. Part 4: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Furmonertinib Mesilate.

06

What researchers measure

Primary outcomes

  1. Nature and frequency of dose-limiting toxicity (DLT)

    The purpose of DLT is to find maximum tolerated dose (MTD).

    Time frame: 21 days after the first dose was administered to each subject.

  2. Nature and frequency of adverse events (AEs)

    Nature and frequency of AEs with severity is aim to evaluate the safety of YL202 combination.

    Time frame: 42 days after the end of treatment (EOT).

Secondary outcomes

  1. Objective response rate (ORR)

    ORR: defined as the proportion of patients who achieved a best overall response of complete response (CR) or partial response (PR).

    Time frame: Up to approximately 3 years.

  2. Characterize Pharmacokinetics (PK) parameter AUC

    The area under curve: AUC is the total amount of YL217 in bloodstream after drug administration.

    Time frame: Up to approximately 3 years

  3. Characterize Pharmacokinetics (PK) parameter Cmax

    Maximum concentration: The highest measured concentration of YL217 in the bloodstream.

    Time frame: Up to approximately 3 years

  4. Characterize Pharmacokinetics (PK) parameter Ctrough

    Trough concentration

    Time frame: Up to approximately 3 years

  5. Characterize Pharmacokinetics (PK) parameter Tmax

    Time to maximum observed concentration

    Time frame: Up to approximately 3 years

  6. Characterize Pharmacokinetics (PK) parameter CL

    Clearance: defined as the amount of drug removed from the bloodstream by the body per unit of time

    Time frame: Up to approximately 3 years

  7. Characterize Pharmacokinetics (PK) parameter Vd

    volume of distribution

    Time frame: Up to approximately 3 years

  8. Characterize Pharmacokinetics (PK) parameter t1/2

    Half-life time:defined as the time it takes for the concentration of the drug in plasma or serum to be reduced by 50%

    Time frame: Up to approximately 3 years

  9. Immunogenicity endpoint: Incidence of anti-YL202 antibody (ADAs).

    The presence of ADAs in patients treated with YL202 will be assessed to evaluate immunogenicity.

    Time frame: Up to approximately 3 years

07

Study locations

1 of 20 sites recruiting
  • Anhui Provincial Hospital(The First Affiliated Hospital of Ustc)
    Hefei, Anhui 230001, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510555, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Meizhou People's Hospital(Huangtang Hospital)Meizhou Academy of Medical Sciences
    Meizhou, Guangdong 514031, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Ghang xi Medical University Cancer Hospital
    Nanning, Guangxi 530028, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Affiliated Hospital Of Hebei University
    Baoding, Hebei 71051, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Anyang Cancer Hospital
    Anyang, Henan 455100, China
    Not yet recruiting
    • Study Coordinator · Contact
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 471023, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Xiangyang Central Hospital
    Xiangyang, Hubei 441138, China
    Not yet recruiting
    • Study Coordinator · Contact
  • The First People's Hospital of Changde City
    Changde, Hunan 415000, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Jiangsu Province Hospital(The First Affiliated Hospital With Nanjing Medical University, Jiangsu Women And Children Health Hospital)
    Nanjing, Jiangsu 210029, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Affiliated Zhongshan Hospital Dalian University
    Dalian, Liaoning 116001, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Liaoning cancer hospital &institute
    Shenyang, Liaoning 110042, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Affiliated Zhongshan Hospital Dalian University
    Jinan, Shandong 250117, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 201321, China
    Recruiting
    • Study Coordinator · Contact
  • Shanxi Cancer Hospital
    Taiyuan, Shanxi 30013, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital
    Sichuan, Sichuan 610072, China
    Not yet recruiting
    • Study Coordinator · Contact
  • Tianjin Cancer Hospital Airport Hospital
    Tianjin, Tianjin Municipality 300300, China
    Not yet recruiting
    • Study Coordinator · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 11 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 11 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 12, 2025
StartActual
Sep 2, 2025
Primary completionEst.
Sep 1, 2026
CompletionEst.
Nov 30, 2027
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07169994
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
Sep 2, 2025
Primary completion
Sep 1, 2026 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Sep 12, 2025

Study contacts

Ning Wang, MM
Contact
info@medilinkthera.com
+86 0512-62858368

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Beruzatatug pelitecan · Toripalimab · Aflutinib

Start the discussion